secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001437749-25-010211
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q4 net loss $31.4M; BLA resubmitted for narsoplimab; PDUFA Sept 2025
---------------------------------------------------------------------------

- Net loss Q4 2024 $31.4M ($0.54/sh) vs Q3 $32.2M; FY2024 loss $156.8M vs $117.8M prior year.
- Cash and investments $90.1M at Dec 31, 2024, down $81.7M from year-end 2023; $42.7M cost outlays.
- OMIDRIA royalties Q4 $10.1M on Rayner sales $33.6M, up from $9.3M on $31.0M in Q3.
- BLA for narsoplimab in TA-TMA resubmitted to FDA Mar 2025; PDUFA target September 2025.
- Phase 3 for zaltenibart in PNH initiated; NIDA awarded $4.02M for OMS527 CUD study; data readout by year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925010211/0001437749-25-010211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774925010211/omer20241119_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-010211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer